Well, that point is interesting BB. Perhaps their IP will have strengthened with these results, but sufficiently to prevent any generics until 2029 is still very much an open question. Unless you or someone else can provide something definitive, instead of pretending you know and that it’s rock solid. If it really was, those other two cos would have settled with AMRN too, and Teva wouldn’t have a clause in their agreement stating all bets are off if another V generic hits the market.
Market Data 
Markets 
AI
